<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have previously shown that exogenous <z:chebi fb="9" ids="16796">melatonin</z:chebi> improves the preservation of the blood-brain barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>) and neurovascular unit following <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>-reperfusion </plain></SENT>
<SENT sid="1" pm="."><plain>Recent evidence indicates that postischemic microglial activation exaggerates the damage to the <z:chebi fb="2" ids="33602">BBB</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Herein, we explored whether <z:chebi fb="9" ids="16796">melatonin</z:chebi> mitigates the cellular <z:mp ids='MP_0001845'>inflammatory response</z:mp> after transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> for 90 min in rats </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="9" ids="16796">Melatonin</z:chebi> (5 mg/kg) or vehicle was given intravenously at reperfusion <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Immunohistochemistry and flow cytometric analysis were used to evaluate the cellular <z:mp ids='MP_0001845'>inflammatory response</z:mp> at 48 hr after reperfusion </plain></SENT>
<SENT sid="5" pm="."><plain>Relative to controls, <z:chebi fb="9" ids="16796">melatonin</z:chebi>-treated animals did not have significantly changed systemic cellular <z:mp ids='MP_0001845'>inflammatory responses</z:mp> in the bloodstream (P &gt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="9" ids="16796">Melatonin</z:chebi>, however, significantly decreased the cellular <z:mp ids='MP_0001845'>inflammatory response</z:mp> by 41% (P &lt; 0.001) in the ischemic hemisphere </plain></SENT>
<SENT sid="7" pm="."><plain>Specifically, <z:chebi fb="9" ids="16796">melatonin</z:chebi> effectively decreased the extent of neutrophil emigration (Ly6G-positive/CD45-positive) and macrophage/activated microglial infiltration (CD11b-positive/CD45-positive) by 51% (P &lt; 0.01) and 66% (P &lt; 0.01), respectively, but did not significantly alter the population composition of T lymphocyte (CD3-positive/CD45-positive; P &gt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>This <z:chebi fb="9" ids="16796">melatonin</z:chebi>-mediated decrease in the cellular <z:mp ids='MP_0001845'>inflammatory response</z:mp> was accompanied by both reduced <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> and improved neurobehavioral outcome by 43% (P &lt; 0.001) and 50% (P &lt; 0.001), respectively </plain></SENT>
<SENT sid="9" pm="."><plain>Thus, intravenous administration of <z:chebi fb="9" ids="16796">melatonin</z:chebi> upon reperfusion effectively decreased the emigration of circulatory neutrophils and macrophages/monocytes into the injured brain and inhibited focal microglial activation following <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>-reperfusion </plain></SENT>
<SENT sid="10" pm="."><plain>The finding demonstrates <z:chebi fb="9" ids="16796">melatonin</z:chebi>'s inhibitory ability against the cellular <z:mp ids='MP_0001845'>inflammatory response</z:mp> after <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>-reperfusion, and further supports its pleuripotent neuroprotective actions suited either as a monotherapy or an add-on to the thrombolytic therapy for <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> patients </plain></SENT>
</text></document>